This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform To Bolster Expanded Lab Operations

BOSTON, Nov. 1, 2012 /PRNewswire/ -- Cartagenia, the world leader in providing genetic labs and clinicians software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today that it has signed a license agreement for the Cartagenia BENCH lab CNV platform with CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company.

Irvine, CA-based CombiMatrix is a CLIA-certified and CAP-accredited, publicly-owned commercial clinical laboratory offering DNA-based genomic testing services in the areas of prenatal and pediatric developmental disorders and oncology. CombiMatrix has established itself as an industry leader in microarray-based clinical testing via a core team of microarray-pioneering physicians, scientists and technicians and has a strong commitment to both client and patient-focused service.

BENCH will be used for the analysis, interpretation and reporting of microarray results in routine postnatal and prenatal settings. The flexible nature of the BENCH platform will allow it to be tailored to CombiMatrix's variant assessment and reporting workflow, significantly accelerating the interpretation and reporting process without disrupting the established operating procedures. Additionally, BENCH's architecture will allow integration and communication with existing IT systems at CombiMatrix.

Richard D. Hockett, Jr., M.D.,Chief Medical Officer at CombiMatrix remarked, "With our lab operations and test volumes growing, it made perfect sense to select the Cartagenia BENCH platform at this time. We already perform hundreds of microarray analyses per month and having recently expanded testing for the prenatal marketplace, that number will grow even more. The automation provided by BENCH lab CNV gives us the ability to grow our array throughput while providing significant savings in both analysis and interpretation time and staffing. Another deciding factor was that Cartagenia clearly positions its solutions for clinical use in contrast to other software packages."

"We are pleased and excited to be working with CombiMatrix," said Drew Arnold, Cartagenia's VP of Sales, North America. "Its selection of the BENCH platform is a strong validation of our approach and indicative of the efficiencies that BENCH can bring to diagnostic laboratories."

Cartagenia successfully went through the process of implementing an ISO-certified quality management system and has registered the BENCH platform for variant interpretation and reporting as a Class 1 Medical Device with the FDA.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,886.07 -26.04 -0.15%
S&P 500 1,966.36 -3.59 -0.18%
NASDAQ 4,454.8850 +12.1870 0.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs